• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾下型腹主动脉瘤腔内修复术后一年的瘤囊动态变化与再次干预及破裂相关。

One-year aneurysm-sac dynamics are associated with reinterventions and rupture following infrarenal endovascular aneurysm repair.

作者信息

Rastogi Vinamr, O'Donnell Thomas F X, Marcaccio Christina L, Patel Priya B, Varkevisser Rens R B, Yadavalli Sai Divya, de Bruin Jorg L, Verhagen Hence J M, Patel Virendra I, Schermerhorn Marc L

机构信息

Department of Surgery, Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.

Division of Vascular Surgery and Endovascular Interventions, Columbia University Irving Medical Center, New York, NY.

出版信息

J Vasc Surg. 2024 Feb;79(2):269-279. doi: 10.1016/j.jvs.2023.10.006. Epub 2023 Oct 14.

DOI:10.1016/j.jvs.2023.10.006
PMID:37844849
Abstract

OBJECTIVE

One-year aneurysm sac changes have previously been found to be associated with mortality and may have the potential to guide personalized follow-up following endovascular aneurysm repair (EVAR). In this study, we examined the association of these early sac changes with long-term reintervention and rupture.

METHODS

We identified all patients undergoing first-time EVAR for intact abdominal aortic aneurysm between 2003 and 2018 in the Vascular Quality Initiative with linkage to Medicare claims for long-term outcomes. We included patients with an imaging study at 1 year postoperatively. Aneurysm sac behavior was defined as per the Society for Vascular Surgery guidelines: stable sac (<5 mm change), sac regression (≥5 mm), and sac expansion (≥5 mm). Outcomes included mortality, reintervention, and rupture within 8 years, which were assessed with Kaplan-Meier methods and multivariable Cox regression analysis. Secondarily, we utilized polynomial spline interpolation to demonstrate the continuous relationship of diameter change to 8-year hazard of reintervention, rupture, or mortality as a composite outcome.

RESULTS

Of 31,185 EVAR patients, 16,102 (52%) had an imaging study at 1 year and were included in this study. At 1 year, 44% of sacs remained stable, 49% regressed, and 6.2% displayed expansion. Following risk adjustment, compared with a stable sac at 1 year, sac regression was associated with lower 8-year mortality (49% vs 53%; hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.85-0.99; P = .036), reintervention rate (8.9% vs 15%; HR, 0.58; 95% CI, 0.50-0.68; P < .001), and rupture rate (2.0% vs 4.0%; HR, 0.45; 95%CI, 0.29-0.69; P < .001). Conversely, compared with a stable sac, sac expansion was associated with higher 8-year mortality (64% vs 53%; HR, 1.31; 95% CI, 1.14-1.51; P < .001) and reintervention rate (27% vs 15%; HR, 1.98; 95% CI, 1.57-2.51; P < .001), but similar risk of rupture (7.2% vs 4.0%; HR, 1.61; 95% CI, 0.88-2.96; P = .12). Polynomial spline interpolation demonstrated that, compared with no diameter change at 1 year, increased sac regression was associated with an incrementally lower risk of late outcomes, whereas increased sac expansion was associated with an incrementally higher risk of late outcomes.

CONCLUSIONS

Following EVAR, compared with a stable sac at 1-year imaging, sac regression and expansion are associated with a lower and higher risk respectively of long-term mortality, reinterventions, and ruptures. Moreover, the amount of regression or expansion seems to be incrementally associated with these late outcomes, too. Future studies are needed to determine how to improve 1-year sac regression, and whether it is safe to extend follow-up intervals for patients with regressing sacs.

摘要

目的

此前已发现动脉瘤囊一年变化与死亡率相关,且可能有潜力指导血管内动脉瘤修复术(EVAR)后的个性化随访。在本研究中,我们探讨了这些早期囊变化与长期再次干预和破裂之间的关联。

方法

我们在血管质量倡议组织中确定了2003年至2018年间所有因完整腹主动脉瘤首次接受EVAR的患者,并将其与医疗保险索赔数据相联系以获取长期预后信息。我们纳入了术后1年进行影像学检查的患者。动脉瘤囊行为根据血管外科学会指南定义为:囊稳定(变化<5毫米)、囊缩小(≥5毫米)和囊扩张(≥5毫米)。结局包括8年内的死亡率、再次干预和破裂,采用Kaplan-Meier方法和多变量Cox回归分析进行评估。其次,我们利用多项式样条插值法来展示直径变化与作为复合结局的8年再次干预、破裂或死亡风险之间的连续关系。

结果

在31185例EVAR患者中,16102例(52%)在1年时进行了影像学检查并纳入本研究。1年时,44%的囊保持稳定,49%缩小,6.2%扩张。经过风险调整后,与1年时囊稳定的患者相比,囊缩小与8年较低的死亡率相关(49%对53%;风险比[HR],0.92;95%置信区间[CI],0.85 - 0.99;P = 0.036)、再次干预率相关(8.9%对15%;HR,0.58;95%CI,0.50 - 0.68;P < 0.001)以及破裂率相关(2.0%对4.0%;HR,0.45;95%CI,0.29 - 0.69;P < 0.001)。相反,与囊稳定的患者相比,囊扩张与8年较高的死亡率相关(64%对53%;HR,1.31;95%CI,1.14 - 1.51;P < 0.001)和再次干预率相关(27%对15%;HR,1.98;95%CI,1.57 - 2.51;P < 0.001),但破裂风险相似(7.2%对4.0%;HR,1.61;95%CI,0.88 - 2.96;P = 0.12)。多项式样条插值法表明,与1年时直径无变化相比,囊缩小增加与晚期结局风险逐渐降低相关,而囊扩张增加与晚期结局风险逐渐升高相关。

结论

EVAR术后,与1年影像学检查时囊稳定的情况相比,囊缩小和扩张分别与长期死亡率、再次干预和破裂的较低和较高风险相关。此外,缩小或扩张的程度似乎也与这些晚期结局逐渐相关。未来需要开展研究以确定如何改善1年时的囊缩小情况,以及对于囊缩小的患者延长随访间隔是否安全。

相似文献

1
One-year aneurysm-sac dynamics are associated with reinterventions and rupture following infrarenal endovascular aneurysm repair.肾下型腹主动脉瘤腔内修复术后一年的瘤囊动态变化与再次干预及破裂相关。
J Vasc Surg. 2024 Feb;79(2):269-279. doi: 10.1016/j.jvs.2023.10.006. Epub 2023 Oct 14.
2
Aneurysm sac failure to regress after endovascular aneurysm repair is associated with lower long-term survival.血管内动脉瘤修复后瘤囊未退缩与长期生存率降低有关。
J Vasc Surg. 2019 Feb;69(2):414-422. doi: 10.1016/j.jvs.2018.04.050. Epub 2018 Jun 28.
3
Association between diabetes status and long-term outcomes following open and endovascular repair of infrarenal abdominal aortic aneurysms.糖尿病状况与内脏动脉瘤开放和血管内修复术后长期结局的关系。
J Vasc Surg. 2024 Dec;80(6):1685-1696.e1. doi: 10.1016/j.jvs.2024.08.030. Epub 2024 Aug 23.
4
Longer follow-up intervals following endovascular aortic aneurysm repair are safe and appropriate after marked aneurysm sac regression.在腹主动脉瘤修复后,明显的瘤囊回缩后,延长随访间隔是安全且合适的。
J Vasc Surg. 2022 Aug;76(2):454-460. doi: 10.1016/j.jvs.2022.01.079. Epub 2022 Jan 29.
5
Aneurysm sac expansion is independently associated with late mortality in patients treated with endovascular aneurysm repair.动脉瘤囊体扩张与血管内动脉瘤修复治疗患者的晚期死亡率独立相关。
J Vasc Surg. 2018 Jan;67(1):157-164. doi: 10.1016/j.jvs.2017.06.075. Epub 2017 Aug 31.
6
Disparities in 5-year outcomes and imaging surveillance following elective endovascular repair of abdominal aortic aneurysm by sex, race, and ethnicity.性别、种族和民族对择期腹主动脉瘤腔内修复术后 5 年结局和影像学监测的影响差异。
J Vasc Surg. 2022 Nov;76(5):1205-1215.e4. doi: 10.1016/j.jvs.2022.03.886. Epub 2022 May 13.
7
Aneurysm Sac Dynamics and its Prognostic Significance Following Fenestrated and Branched Endovascular Aortic Aneurysm Repair.覆膜支架开窗及分支腔内修复术后动脉瘤瘤腔动力学变化及其对预后的影响
Eur J Vasc Endovasc Surg. 2024 May;67(5):728-736. doi: 10.1016/j.ejvs.2023.11.033. Epub 2023 Nov 22.
8
Incidence, reintervention, and survival associated with type II endoleak at hospital discharge after elective endovascular aneurysm repair in the Vascular Quality Initiative.在血管质量倡议中,择期血管内动脉瘤修复术后出院时 II 型内漏与再干预和生存的关系。
J Vasc Surg. 2023 Sep;78(3):679-686.e1. doi: 10.1016/j.jvs.2023.05.041. Epub 2023 May 29.
9
Late outcomes after endovascular and open repair of large abdominal aortic aneurysms.大型腹主动脉瘤血管内修复术和开放修复术后的远期疗效
J Vasc Surg. 2021 Oct;74(4):1152-1160. doi: 10.1016/j.jvs.2021.02.024. Epub 2021 Mar 6.
10
Reinterventions and sac dynamics after fenestrated endovascular aortic repair with physician-modified endografts for index aneurysm repair and following proximal failure of prior endovascular aortic repair.使用医生改良型腔内移植物进行开窗型腔内主动脉修复术治疗初发动脉瘤以及在先前行腔内主动脉修复术近端失败后的再次干预和囊袋动态变化
J Vasc Surg. 2024 Jun;79(6):1287-1294.e1. doi: 10.1016/j.jvs.2024.01.002. Epub 2024 Jan 5.

引用本文的文献

1
Implications of preoperative arterial stiffness for patients treated with endovascular repair of abdominal aortic aneurysms.术前动脉僵硬度对接受腹主动脉瘤血管腔内修复术患者的影响。
JVS Vasc Sci. 2024 May 21;5:100209. doi: 10.1016/j.jvssci.2024.100209. eCollection 2024.
2
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm.前蛋白转化酶枯草溶菌素 9 作为腹主动脉瘤的药物靶点。
Curr Opin Lipidol. 2024 Oct 1;35(5):241-247. doi: 10.1097/MOL.0000000000000945. Epub 2024 Jul 22.